MA1-12692

antibody from Invitrogen Antibodies

Targeting: ESR1 ER-alpha, Era, ESR, NR3A1

Provider product page for MA1-12692

Western blot

Immunoprecipitation

Blocking/Neutralizing

Gel shift

Chromatin Immunoprecipitation

Other assay

Antibody data

Antibody Data
Antigen structure
References [73]
Comments [0]
Validations
Western blot [3]
Other assay [2]

Submit

Product number: MA1-12692 - Provider product page
Provider: Invitrogen Antibodies
Product name: Estrogen Receptor alpha Monoclonal Antibody (TE111.5D11)
Antibody type: Monoclonal
Antigen: Other
Description: A suggested positive control for this product is T47D cells.
Reactivity: Human, Mouse, Rat, Bovine, Canine, Chicken/Avian, Hamster, Porcine, Rabbit
Host: Mouse
Isotype: IgG
Antibody clone number: TE111.5D11
Vial size: 100 µg
Concentration: 1 mg/mL
Storage: -20° C, Avoid Freeze/Thaw Cycles

ESR1 protein structure - MA1-12692 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 Nron regulates ERalpha stability in osteoclasts. a RNA pull-down assay and b RNA immunoprecipitation assay in mouse osteoclasts showed specific interaction between Nron and ubiquitin E3 ligase CUL4B. The experiment was repeated three times independently with similar results. c, d Expression of ERalpha in osteoclasts with Nron overexpression (OVE) or knockdown (K.D) analyzed by western blot (WB). The graph shows the relative ERalpha density (ERalpha/GAPDH levels, n = 3 biologically independent experiments). e Expression of Esr1 gene in osteoclasts with Nron overexpression or knockdown analyzed by Q-PCR, ( n = 3 biologically independent experiments). f The protein stability (t1/2) and the proteasome-mediated degradation of ERalpha assessed by measuring the decline of protein levels after CHX (10 mug/ml) or CHX (10 mug/ml) + MG132 (20 muM) treatment in osteoclasts. The experiment was repeated three times independently with similar results. g The ubiquitination of ERalpha in Nron overexpression or knockdown osteoclasts was assessed by immunoprecipitation (IP) with anti-ERalpha antibody followed by ubiquitin WB analysis. The experiment was repeated three times independently with similar results. h Forty-eight hours after scramble or Cul4b siRNA transfection in Nron knockdown or control osteoclasts, the cells were treated with 20 muM MG132 for 6 h, then the abundance of ubiquitinated ERalpha was assessed by IP with anti-ERalpha antibody followed by ubiquitin WB analysis. The

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6 Functional motif of Nron interacts with Cul4b to regulate ERalpha ubiquitination. a Genome browser depiction of Nron and its conserved analogs in multiple species. b Evolutional tree of NCM1 and NCM2 in multiple species. c Expression of ERalpha in osteoclasts with Nron, NCM1, or NCM2 overexpression analyzed by WB. The experiment was repeated three times independently with similar results. d Expression of ERalpha in human THP-1 derived osteoclast with NRON, NCM1(h), NCM2(h) overexpression were analyzed by WB. The experiment was repeated three times independently with similar results. e Schematic diagram illustrating the mutation strategies of Nron. f Interactions of Nron and Nron mutants with CUL4B determined by RNA pull-down assay in mouse osteoclast lysates. The experiment was repeated three times independently with similar results. g The ubiquitination of ERalpha in Nron or NCM2 overexpression osteoclasts were assessed by immunoprecipitation (IP) with anti-ERalpha antibody followed by ubiquitin WB analysis. The experiment was repeated three times independently with similar results. Source data are provided as a Source Data file.